Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation
    Meeting Abstract

    Dagogo-Jack, I.; Dowlati, A.; Guo, R.; Awad, M. M.; Swalduz, A.; Calvo, E.; Garcia, V. M.; Adjei, A. A.; Lorusso, P.; Punekar, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer
    Meeting Abstract

    Drilon, A.; Shen, L.; van Tilburg, C.; Doz, F.; Tan, D. S. W.; Lin, J. J.; Kummar, S.; Lassen, U. N.; McDermott, R. S.; Dierselhuis, M. P.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2ep53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours
    Meeting Abstract

    Schoeffski, P.; Lorusso, P.; Yamamoto, N.; Lugowska, I.; Garcia, V. M.; Lauer, U.; Hu, C.; Jayadeva, G.; Lahmar, M.; Gounder, M.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Response of thrombopoietin receptor agonists in MDM2 inhibitor induced thrombocytopenia
    Meeting Abstract

    DeMatteo, R.; Sgroe, E.; Merrill, M. B.; Gounder, M.; Liu, D.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Preclinical and ongoing phase I study data of the CHK1 inhibitor BBI-355 in development for patients with oncogene amplification on extrachromosomal DNA (ecDNA)
    Meeting Abstract

    Drilon, A.; Rivera, I. I. R.; Spira, A. I.; Sharma, M. R.; Hansen, R.; Chowdhry, S.; Kasibhatla, S.; Tewari, A.; Weymer, S.; Wagner, K.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
    Meeting Abstract

    Marathe, O.; Cheng, Y.; Spira, A. I.; Hamilton, E. P.; Rubinstein, M. M.; Dong, X.; Li, L.; Lv, D.; Shi, J.; Gabrail, N.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study
    Meeting Abstract

    Patel, M. R.; Doi, T.; Koyama, T.; Falchook, G. S.; Friedman, C. F.; Piha-Paul, S. A.; Gutierrez, M.; Awad, M. M.; Mattour, A. H.; Satoh, T.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Arbour, K. C.; Punekar, S.; Garrido-Laguna, I.; Hong, D. S.; Wolpin, B.; Pelster, M. S.; Barve, M.; Starodub, A.; Sommerhalder, D.; Chang, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study
    Meeting Abstract

    Li, B. T.; Meric-Bernstam, F.; Bardia, A.; Naito, Y.; Siena, S.; Aftimos, P. G.; Anderson, I.; Curigliano, G.; Luken, M. J. D.; Kalra, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer
    Meeting Abstract

    Hong, D. S.; Xu, R. H.; McDermott, R. S.; Shen, L.; Dierselhuis, M. P.; Doz, F.; Tahara, M.; Bernard-Gauthier, V.; Norenberg, R.; Brega, N.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save